{"disease":{"id":"natural-killer-t-cell-lymphoma","name":"natural killer t cell lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06314334","title":"Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":210,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06255795","title":"The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":142,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT07409168","title":"Multi-modal Fusion Model and Deep Learning for Predicting Treatment Response in NKTCL","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06583083","title":"Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03595657","title":"A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"CStone Pharmaceuticals","has_results":true},{"nct_id":"NCT05343377","title":"A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":72,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT03623087","title":"SIMPLE Chemotherapy for NK Lymphoma/Leukaemia","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":68,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT06966154","title":"A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":68,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05058755","title":"Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT04366128","title":"Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL","phase":"NA","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Rong Tao","has_results":false},{"nct_id":"NCT03936452","title":"Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05464433","title":"Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":46,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06376721","title":"Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":43,"lead_sponsor_name":"Beijing Tongren Hospital","has_results":false},{"nct_id":"NCT04004572","title":"Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":37,"lead_sponsor_name":"Rong Tao","has_results":false},{"nct_id":"NCT04763616","title":"Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"Won Seog Kim","has_results":false},{"nct_id":"NCT03618238","title":"Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT04288726","title":"Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Baylor College of Medicine","has_results":false},{"nct_id":"NCT02722668","title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT06793956","title":"Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT02991898","title":"Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}